Related Experiment Videos
Gemcitabine
1Department of Medicine, Royal Marsden Hospital, Sutton, Surrey.
Abstract:
There is widespread consensus that a plateau has been reached in the effectiveness of known DNA interactive drugs against most malignancies. Combination treatments, dose intensification and schedule alterations (e.g. infusional and neoadjuvant treatments) represent exciting research opportunities and possibly the means for making meaningful progress. However, frustration with the slow pace of even these most novel approaches has led to a search for newer drug targets and great expectations of new drugs.
Insights
The effectiveness of current DNA-targeting cancer drugs has plateaued. Researchers are exploring combination therapies, dose changes, and new drug targets to improve cancer treatment outcomes.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- A plateau in efficacy has been observed with existing DNA-interactive drugs across numerous malignancies.
- Current treatment strategies, including combination therapies and dose/schedule alterations, offer limited but notable progress.
Purpose of the Study:
- To address the stagnation in cancer drug effectiveness.
- To explore novel therapeutic strategies beyond established DNA-interactive agents.
Main Methods:
- Investigating combination treatments.
- Examining dose intensification and altered treatment schedules (e.g., infusional, neoadjuvant).
- Identifying and evaluating new drug targets.
Main Results:
- Established DNA-interactive drugs show limited effectiveness against many cancers.
- Novel approaches like combination therapies and altered schedules present research opportunities.
- Progress with novel strategies has been slower than anticipated, prompting a search for new targets.
Conclusions:
- Further research into combination treatments, dose/schedule modifications, and novel drug targets is crucial for advancing cancer therapy.
- The development of new drugs targeting different mechanisms is highly anticipated to overcome current treatment limitations.